Revenue segments as reported by the company.

Life Sciences Solutions

Analytical Instruments

Specialty Diagnostics

Laboratory Products and Services

Eliminations

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Amortization of acquisition-related intangible assets

Research and development

Restructuring and other costs

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Thermo Fisher Scientific

Life Technologies was a biotech company founded in November 2008 through a US$6.7 billion merger of Invitrogen Corporation and Applied Biosystems Inc. The joint sales of the combined companies were about $3.5 billion; they had about 9,500 employees, and owned more than 3,600 licenses and patents.

Life Technologies

Thermo Fisher Scientific, Inc. engages in the provision of analytical instruments, equipment, reagents and consumables, software, and services for research, analysis, discovery, and diagnostics. It operates through the following segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services. The Life Sciences Solutions segment is composed of a portfolio of reagents, instruments, and consumables used in biological and medical research, discovery and production of new drugs and vaccines, as well as diagnosis of infection and disease. The Analytical Instruments segment offers instruments, consumables, software, and services that are used for a range of applications in the laboratory, on the production line, and in the field. The Specialty Diagnostics segment provides diagnostic test kits, reagents, culture media, instruments, and associated products used to increase the speed and accuracy of diagnoses. The Laboratory Products and Services segment is involved in providing everything needed for the laboratory, including a combination of self-manufactured and sourced products for customers in research, academic, government, industrial, and healthcare settings. The company was founded on October 11, 1960 and is headquartered in Waltham, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Thermo Fisher excels in 2022, eyes growth amid challenges

Thermo Fisher Scientific delivered exceptional 2022 results with strong Q4 performance and robust full-year revenue. Growth strategy and segment strengths position the company well for continued success in 2023.
Challenges such as normalization of growth, margin influences, and market dynamics require strategic management. Opportunities in high-growth markets and next-gen technologies offer avenues for further expansion and value creation.
Maintaining a focus on innovation, sustainability, and operational efficiency will be key to navigating challenges and capitalizing on growth opportunities in 2023.
Overall, Thermo Fisher Scientific's solid financial performance, strategic focus, and market positioning set a positive trajectory for continued success and value creation in the coming year.

Thermo Fisher excels in Q1 despite COVID challenges, eyes growth

Thermo Fisher Scientific's Q1 2023 showcased resilience amid challenges, driven by innovation and strategic initiatives. While facing short-term headwinds, the company remains well-positioned for long-term growth through market opportunities and operational strengths.

Thermo Fisher faces market challenges, focuses on cost management and acquisitions

Thermo Fisher Scientific navigated a challenging macroeconomic environment in Q2 2023, with varied performance across end markets. The company is focused on managing costs, driving productivity, and pursuing strategic acquisitions to enhance capabilities. Despite challenges, Thermo Fisher remains committed to ESG priorities and market outperformance.

Thermo Fisher reports solid Q3 earnings, eyes growth opportunities

Thermo Fisher Scientific's Q3 performance was solid, with revenue growth and strategic acquisitions driving market position strengthening.
While facing challenges like revenue impact in Q4 and customer caution, the company remains optimistic about industry outlook and growth opportunities.
The company's focus on innovation, ESG priorities, and operational efficiency positions it well for future growth and success.
Management's insights into 2024 outlook indicate a balanced approach to growth through strategic investments and operational improvements.

Thermo Fisher posts solid earnings, eyes growth amid market challenges

Thermo Fisher Scientific delivered strong financial performance in Q4 2023 and full-year 2023, driven by innovation and customer focus.
While facing challenges in certain segments and markets, the company remains optimistic about growth opportunities and market outpacing.
Strategic acquisitions, focus on sustainability, and operational excellence position Thermo Fisher for continued success in 2024 and beyond.
Guidance for 2024 indicates a focus on organic growth, stable segment margins, and a commitment to long-term market outperformance.

Thermo Fisher reports strong Q1 earnings, eyes growth opportunities

Thermo Fisher Scientific's Q1 2024 earnings call highlighted strong financial performance driven by a proven growth strategy and disciplined capital deployment. While facing challenges in certain end markets and regulatory uncertainties, the company remains optimistic about future growth opportunities. Key strengths include innovation, strategic partnerships, and a focus on corporate social responsibility.

Thermo Fisher excels in Q2, raises 2024 guidance amid market challenges

Thermo Fisher Scientific's Q2 performance reflects resilience and strategic focus amidst market challenges. The company's emphasis on innovation, operational efficiency, and customer relationships positions it well for sustained growth. With a positive outlook for 2024 and a commitment to long-term success, Thermo Fisher remains a strong player in the industry.

Thermo Fisher excels in Q3 earnings, eyes growth opportunities

Thermo Fisher Scientific's Q3 2024 earnings call showcased strong financial performance, strategic innovations, and growth opportunities.
While facing challenges in certain market segments, the company's focus on innovation, partnerships, and financial strength positions it well for future growth.
With raised EPS guidance and revenue expectations, Thermo Fisher is poised for continued success through market expansion and strategic initiatives.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Shares of Thermo Fisher Scientific Inc. TMO, +0.73% were down 0.1% in premarket trading on Tuesday, the day after the Food and Drug Administration sent an alert warning health care providers about a risk of false-positive results when using the TaqPath COVID-19 test.

FDA warns providers about problems with Thermo Fisher's COVID-19 test

Boise Cascade

PulteGroup

Superior Uniform Group

Werner Enterprises

Stocks that have a strong history of dividend growth, as opposed to those that offer high yields, form a healthy portfolio with more scope for capital appreciation.

5 Top-Ranked Dividend Growth Stocks Still At Bargain Prices

Becton, Dickinson and Co.

Pfizer

High costs make drug developers unlikely picks for the Oracle of Omaha.

Why Warren Buffett Might Not Be Crazy About Biopharma Stocks

QIAGEN

Thermo Fisher Scientific said on Thursday it has terminated its acquisition agreement for German genetic testing company Qiagen as the minimum acceptance threshold to its tender offer were not met.

Thermo Fisher ends deal agreement for genetic testing firm Qiagen

WALTHAM, Mass., Aug. 13, 2020 /PRNewswire/ -- Thermo Fisher Scientific Inc.

Thermo Fisher Scientific Announces Results of Offer to Acquire QIAGEN, Lapse of Offer and Termination of Acquisition Agreement

WALTHAM, Mass., Aug. 12, 2020 /PRNewswire/ -- Thermo Fisher Scientific Inc.

Thermo Fisher Scientific Supports COVID-19 Testing at Historically Black Colleges and Universities Seeking to Provide a Safe Return to Campus

WALTHAM, Mass., Aug. 11, 2020 /PRNewswire/ -- Thermo Fisher Scientific Inc.

Thermo Fisher Scientific Provides Process Overview for the Announcement of Final Offer Results

Edwards Lifesciences

TMO vs. EW: Which Stock Is the Better Value Option?

Männedorf, Switzerland, August 5, 2020 – The Tecan Group (SIX Swiss Exchange: TECN) and Thermo Fisher Scientific (NYSE: TMO), the world leader in serving science, announced today a collaboration to enable scaled-up COVID-19 testing globally. Thermo Fisher Scientific is introducing a new highly automated, real-time PCR solution designed to analyze up to 6,000 samples in a single day to meet increasing global demand for COVID-19 testing. The high-throughput system enables laboratories to double or even triple their testing capacity to support global efforts to return communities back to work and school.

Thermo Fisher Scientific to leverage Tecan’s automation technology to enable scaled-up COVID-19 testing globally

Abbott Labs

Spending on leisure and vice has remained high in recent months, making this sector one to watch during this period of uncertainty.

3 Charts That Suggest Sin Stocks Are Headed Higher

Will Thermo Fisher be able to complete its deal to acquire Qiagen, or will shareholders vote it down?

Thermo Fisher Increases Its Buyout Price for Qiagen, but Investors Ask for More

Thermo Fisher Long Case: Trajectory Is Clear, Buy On Value

LONDON, July 28, 2020 /PRNewswire/ -- Davidson Kempner European Partners, LLP is the sub-adviser to Davidson Kempner Capital Management LP which acts as the discretionary investment manager to various funds which represent 5.1% of the share capital of QIAGEN N.V. (the "Company") Davidson.

Davidson Kempner Expects Thermo Fisher Scientific's Current Offer for QIAGEN N.V. to Fail

Thermo Fisher: A Strong First Semester Doesn't Mean It's Cheap

CARLSBAD, Calif., July 27, 2020 /PRNewswire/ -- Thermo Fisher Scientific today announced the expansion of its GlobalAccess Sequencing Program to include laboratories working in oncology.

Thermo Fisher Scientific Expands GlobalAccess Sequencing Program

Casper Sleep

Thermo Fisher Scientific Inc. (TMO) CEO Marc Casper on Q2 2020 Results - Earnings Call Transcript

The company got a lot of help from COVID-19.

How Thermo Fisher Scientific Trounced Q2 Earnings Estimates

Thermo Fisher earnings and sales comfortably beat second-quarter estimates for the medtech giant. TMO stock rose modestly early Wednesday.

Thermo Fisher Earnings, Sales Growth Top Views; Medtech Extends Run

  Shares of Thermo Fisher Scientific (NYSE:TMO) rose 0.7% after the company reported Q2 results.

Recap: Thermo Fisher Scientific Q2 Earnings

Thermo Fisher Scientific Inc. (NYSE: TMO) published its quarterly financial results on Wednesday that topped analysts’ estimates for earnings and revenue in the second quarter.

Thermo Fisher reports a 10% increase in sales in the second quarter

WALTHAM, Mass., July 22, 2020 /PRNewswire/ -- Thermo Fisher Scientific Inc.

Thermo Fisher Scientific Reports Second Quarter 2020 Results

Thermo Fisher (TMO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Why Earnings Season Could Be Great for Thermo Fisher (TMO)

Chipotle

Quest Diagnostics

Boston Beer Company

Healthcare, consumer staples and retail sectors could be ideal investments right now, keeping in mind the growing demand for their products.

4 Top Stocks to Buy Ahead of Earnings Release

WALTHAM, Mass., July 20, 2020 /PRNewswire/ -- Thermo Fisher Scientific Inc.

Thermo Fisher Scientific's Response to COVID-19 Continues to Expand to Support Development and Production of Therapeutics and Vaccines

Lithia Motors

Pool

We have narrowed down our search to five Zacks Rank #1 stocks slated to release earrings results this week with a positive Earnings ESP.

News for Thermo Fisher Scientific Stock (TMO)